Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 11/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 4/20 | 1.00 |
| ▸ | FGFR2 | P21802 | 4/20 | 1.00 |
| ▸ | FGFR3 | P22607 | 4/20 | 1.00 |
| ▸ | JAK3 | P52333 | 3/20 | 0.69 |
| ▸ | EGFR | P00533 | 6/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29925892 | 0.93 | FGFR4 (0.87) | FGFR4FGFR1FGFR2FGFR3JAK3 | |
| SCHEMBL19441991 | 0.92 | FGFR4 (0.84) | FGFR4FGFR1FGFR2FGFR3JAK3 | |
| SCHEMBL17857066 | 0.90 | FGFR4 (0.82) | FGFR4FGFR1FGFR2FGFR3JAK3 | |
| SCHEMBL17209937 | 0.88 | JAK3 (0.84) | FGFR4FGFR1FGFR2FGFR3JAK3 | |
| SCHEMBL24490215 | 0.88 | FGFR4 (0.78) | FGFR4FGFR1FGFR2FGFR3JAK3 | |
| SCHEMBL22532594 | 0.83 | FGFR4 (0.71) | FGFR4FGFR1FGFR2FGFR3JAK3 | |
| SCHEMBL22532360 | 0.83 | FGFR4 (0.71) | FGFR4FGFR1FGFR2FGFR3JAK3 | |
| SCHEMBL24490094 | 0.83 | FGFR4 (0.71) | FGFR4FGFR1FGFR2FGFR3JAK3 | |
| SCHEMBL22532562 | 0.82 | FGFR4 (0.70) | FGFR4FGFR1FGFR2FGFR3JAK3 | |
| SCHEMBL22532311 | 0.82 | FGFR4 (0.70) | FGFR4FGFR1FGFR2FGFR3JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122005813-A | Targeted treatment of cancers with deregulated fibroblast growth factor receptor signaling | 法码科思莫斯控股有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-20250353912-A1 | COMPOSITIONS AND METHODS COMPRISING ANTIBODIES THAT BIND TO COVALENT PEPTIDE CONJUGATES | UNIV NEW YORK (US) | 2025-11-20 | — | — | US | claimed |
| US-20250235456-A1 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | IAMBIC THERAPEUTICS, INC. | 2025-07-24 | — | — | US | claimed |
| EP-4543931-A2 | COMPOSITIONS AND METHODS COMPRISING ANTIBODIES THAT BIND TO COVALENT PEPTIDE CONJUGATES | New York University (US) | 2025-04-30 | — | — | EP | claimed |
| CN-119866347-A | Compositions and methods comprising antibodies conjugated to covalent peptide conjugates | 纽约大学 | 2025-04-22 | — | — | CN | claimed |
| CN-119182183-A | Method and system for setting bias of unit load based on spot delivery price clearing mode | 华能临沂发电有限公司 | 2024-12-24 | — | — | CN | claimed |
| US-20240327928-A1 | METHOD FOR IDENTIFYING RESPONSIVENESS TO FIBROBLAST GROWTH FACTOR RECEPTOR 1 INHIBITOR THERAPY | UNIV KOELN (DE) | 2024-10-03 | — | — | US | claimed |
| EP-4423302-A2 | NOVEL KINASE FUSIONS DETECTED BY LIQUID BIOPSY | Foundation Medicine, Inc. (US) | 2024-09-04 | — | — | EP | claimed |
| CN-118414439-A | Novel kinase fusion by liquid biopsy | 基金会医学公司 | 2024-07-30 | — | — | CN | claimed |
| EP-4384639-A1 | METHOD FOR IDENTIFYING RESPONSIVENESS TO FIBROBLAST GROWTH FACTOR RECEPTOR 1 INHIBITOR THERAPY | Universität zu Köln (DE) | 2024-06-19 | — | — | EP | claimed |
| WO-2023077104-A2 | NOVEL KINASE FUSIONS DETECTED BY LIQUID BIOPSY | FOUNDATION MEDICINE, INC. (US) | 2023-05-04 | — | — | WO | claimed |
| WO-2023017133-A1 | METHOD FOR IDENTIFYING RESPONSIVENESS TO FIBROBLAST GROWTH FACTOR RECEPTOR 1 INHIBITOR THERAPY | UNIVERSITÄT ZU KÖLN (DE) | 2023-02-16 | — | — | WO | claimed |
| EP-4134451-A1 | METHOD FOR IDENTIFYING RESPONSIVENESS TO FIBROBLAST GROWTH FACTOR RECEPTOR 1 INHIBITOR THERAPY | Universität zu Köln (DE) | 2023-02-15 | — | — | EP | claimed |
| US-20220412957-A1 | METHODS OF TREATING CANCER PATIENTS WITH RAS NODE OR RTK TARGETED THERAPEUTIC AGENTS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2022-12-29 | — | — | US | claimed |
| EP-4073516-A1 | METHODS OF TREATING CANCER PATIENTS WITH RAS NODE OR RTK TARGETED THERAPEUTIC AGENTS | Celcuity Inc. (US) | 2022-10-19 | — | — | EP | claimed |
| WO-2022174234-A2 | BIOMARKERS FOR CANCER TREATMENT | FOUNDATION MEDICINE, INC. (US) | 2022-08-18 | — | — | WO | claimed |
| EP-4041237-A1 | TARGETED TREATMENT OF CANCERS WITH DYSREGULATED FIBROBLAST GROWTH FACTOR RECEPTOR SIGNALING | G1 Therapeutics, Inc. (US) | 2022-08-17 | — | — | EP | claimed |
| US-11408038-B2 | N-cadherin and FGFR1 and/or FGFR4 for use in predicting the response of patients to a lung cancer treatment and method and kit based on said use | FUNDACIÓN DE INVESTIGACIÓN HOSPITAL 12 DE OCTUBRE | 2022-08-09 | — | — | US | claimed |
| US-20220241275-A1 | TARGETED TREATMENT OF CANCERS WITH DYSREGULATED FIBROBLAST GROWTH FACTOR RECEPTOR SIGNALING | PHARMACOSMOS HOLDING A/S (DK) | 2022-08-04 | — | — | US | claimed |
| CN-114761009-A | Targeted treatment of cancer with deregulated fibroblast growth factor receptor signaling | G1治疗公司 | 2022-07-15 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250235456-A1 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | AZI2, TPMT, HDAC10 | FGFR4 4248/4885FGFR1 3506/4885FGFR2 3828/4885 |
| US-20220241275-A1 | TARGETED TREATMENT OF CANCERS WITH DYSREGULATED FIBROBLAST GROWTH FACTOR RECEPTOR SIGNALING | FGFR1, FGFR2, FGFR3 | FGFR4 4/4885FGFR1 1/4885FGFR2 2/4885 |
| US-20250353912-A1 | COMPOSITIONS AND METHODS COMPRISING ANTIBODIES THAT BIND TO COVALENT PEPTIDE CONJUGATES | MICA, CD74, HLA-DRB1 | FGFR4 3469/4885FGFR1 3437/4885FGFR2 2703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.